Onco Wiki / Bandeira vermelha

Waldenström com biologia molecular adversa: MYD88-wildtype (pobre resposta BTKi — ibrutini...

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDRF-WM-HIGH-RISK-BIOLOGY
TipoSinal de alerta
Estadoreviewed 2026-04-27 | pending_clinical_signoff
DoençasDIS-WM
FontesSRC-ESMO-WM-2024 SRC-NCCN-BCELL-2025

Origem da bandeira vermelha

DefiniçãoWaldenström with adverse molecular biology: MYD88-wildtype (poor BTKi response — ibrutinib/zanubrutinib substantially less active), CXCR4-mutated (delayed BTKi response, may benefit zanubrutinib > ibrutinib per ASPEN trial), TP53-mutated (chemo-resistance), or IPSSWM intermediate-high / high risk. Drives selection of fixed-duration chemoimmuno (BR or Dex-R-Cyclo) over continuous BTKi when MYD88-wildtype.
Direcção clínicaintensificar
Categoriahigh-risk-biology

Lógica de Desencadeamento

{
  "any_of": [
    {
      "finding": "myd88_status",
      "value": "wildtype"
    },
    {
      "finding": "cxcr4_mutation",
      "value": true
    },
    {
      "finding": "tp53_mutation",
      "value": true
    },
    {
      "finding": "ipsswm_high_risk",
      "value": true
    }
  ],
  "type": "biomarker"
}

Notas

MYD88-L265P mutation present in ~95% WM and is the predictive biomarker for BTKi efficacy — MYD88-wildtype WM (~5%) responds poorly to ibrutinib (ORR ~30% vs ~90% for MYD88-mut per Treon series). For MYD88-WT or BTKi-ineligible: BR (bendamustine + rituximab) is preferred fixed-duration regimen. CXCR4 mutations (~30-40% MYD88-mut WM) delay BTKi response and are partially overcome by zanubrutinib (ASPEN trial showed deeper responses vs ibrutinib in CXCR4-mut subset). TP53-mut WM: avoid chemoimmuno; BTKi-based or BCL2-based (venetoclax — Castillo emerging data) preferred.

Usado por

Algoritmos